A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR
inhibitor ceralasertib showed clinical benefit in pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair deficiencies, according to results from the phase I portion of the phase I/II AcSé-ESMART trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19 in Orlando, Florida.
Login Or Register To Read Full Story